Anales de la RANM

152 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PEQUEÑAS MOLÉCULAS EN EL TRATAMIENTO DE LA PSORIASIS Martos-Cabrera L, et al. An RANM. 2023;140(02):142 - 152 28. Reich K, Korge B, Magnolo N et al. Quality- of-life outcomes, effectiveness and tolerability of apremilast in patients with plaque psoriasis and routine German dermatology care: Results from LAPIS-PSO. Dermatol Ther. 2022; 12(1): 203-221. 29. Van Voorhees AS, Stein Gold L, Lebwohl M et al. Efficacy and safety of apremilast in pa- tients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020; 83(1): 96- 103. 30. Kavanaugh A, Gladman DD, Edwards CJ et al. Long-term experience with apremilast in pa- tients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019; 21(1): 118. 31. Bellinato F, Gisondi P, Girolomoni G. Latest ad- vances for the treatment of chronic plaque pso- riasis with biologics and oral small molecules. BTT. 2021; 15(1): 247-253. 32. Lebwohl MG, Papp KA, Stein Gold L et al. Trial of roflumilast cream for chronic plaque psoria- sis. N Engl J Med. 2020; 383(3): 229-239. 33. ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2000 Feb 29. Acceso el 3 de enero 2023. http://clinicaltrials.gov/. 34. Liu X, Chen R, Zeng G et al. Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study. Bioanalysis. 2018; 10(11): 863- 875. 35. Azevedo A, Torres T. Tofacitinib: a new oral therapy for psoriasis. Clin Drug Investig. 2018; 38(2): 101-112. 36. Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a re- view. Dermatol Ther. 2020; 10(1): 29-42. 37. Calautti E, Avalle L, Poli V. Psoriasis: a STAT3- centric view. Int J Mol Sci. 2018; 19(1): 171. 38. Papp K, Pariser D, Catlin M et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to- severe psoriasis. Br J Dermatol. 2015; 173(3): 767-776. 39. Papp KA, Menter MA, Raman M et al. A rando- mized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis. Br J Dermatol. 2016; 174(6): 1266-1276. 40. Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022; 23(6): 813-822. 41. Papp K, Gordon K, Thaçi D et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in pso- riasis. N Engl J Med. 2018; 379(14): 1313-1321. 42. Xu X, Zhang HY. The immunogenetics of pso- riasis and implications for drug repositioning. Int J Mol Sci. 2017; 18(12): 2650. 43. Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest Dermatol. 2011; 131(1): 108-117. 44. Cohen S, Fishman P. Targeting the A3 adeno- sine receptor to treat cytokine release syndro- me in cancer immunotherapy. Drug Des Devel Ther. 2019; 13(1): 491-497. 45. Tang L, Yang X, Liang Y, Xie H, Dai Z, Zheng G. Transcription factor retinoid-related orphan receptor γt: a promising target for the treatment of psoriasis. Front Immunol. 2018; 9(1): 1210. 46. Cervantes-Durán C, Avalos-Viveros M, Torner L et al. The 5-HT1A receptor agonist, 8-OH- DPAT, attenuates long-lasting pain in imiqui- mod-induced psoriasis in mice. Exp Dermatol. 2022; 31(4): 600-607. 47. Yiu ZZ, Warren RB. Novel oral therapies for psoriasis and psoriatic arthritis. Am J Clin Der- matol. 2016; 17(3): 191-200. 48. Steinckwich N, Myers P, Janardhan KS et al. Role of the store-operated calcium entry pro- tein, STIM1, in neutrophil chemotaxis and in- filtration into a murine model of psoriasis-in flamed skin. FASEB J. 2015: 29(7): 3003-3013. Si desea citar nuestro artículo: Martos-Cabrera L, Sampedro-Ruiz R, Llamas-Velasco M, de la Fuente H, Daudén E. Pequeñas moléculas: nuevos horizontes terapéuticos en la psoriasis. An RANM. 2023;140(02): 142– 152. DOI: 10.32440/ ar.2023.140.02 . rev04